Country: Canada
Language: English
Source: Health Canada
AMOXICILLIN (AMOXICILLIN TRIHYDRATE)
APOTEX INC
J01CA04
AMOXICILLIN
125MG
POWDER FOR SUSPENSION
AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 125MG
ORAL
75/100/150ML
Prescription
AMINOPENICILLINS
Active ingredient group (AIG) number: 0131314002; AHFS:
MARKETED
1997-04-15
Page 1 of 21 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICIATION INFORMATION PR APO-AMOXI Amoxicillin (as amoxicillin trihydrate) 125 mg / 5 mL, 250 mg / 5 mL Oral Suspension - Sugar Free Apotex Standard Antibiotic APOTEX INC. DATE OF REVISION: 150 Signet Drive Toronto, Ontario M9L 1T9 September 21, 2022 Submission Control Number: 266761 Page 2 of 21 NAME OF DRUG PR APO-AMOXI Amoxicillin (as amoxicillin trihydrate) THERAPEUTIC CLASSIFICATION Antibiotic ACTION AND CLINICAL PHARMACOLOGY Amoxicillin exerts its bactericidal action by interfering with bacterial cell wall synthesis. INDICATIONS AND CLINICAL USE APO-AMOXI may be indicated in the treatment of infections due to susceptible strains of the following micro-organisms: Gram-negative organisms: H. influenzae, P. mirabilis and N. gonorrhoeae. Gram-positive organisms: Streptococci (including Streptococcus faecalis and Streptococcus pneumoniae). Amoxicillin is not active against Pseudomonas aeruginosa, indole-positive Proteus species, Serratia marcescens, Klebsiella and Enterobacter species. In emergency cases, where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgment while awaiting bacteriologic tests to determine its antimicrobial sensitivity. APO-AMOXI may be indicated as a prophylaxis against alpha-hemolytic (Viridan's group) Streptococci before dental, oral or upper respiratory tract surgery or instrumentation. It may be also indicated as a prophylaxis of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve leaflets. To reduce the development of drug-resistant bacteria and maintain the Read the complete document